tbuckley/cabot-search huggingface dataset:
Phase I study of cabazitaxel-PF induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Authors: Nadia Camille, Rita Babu, Richard Lorne Bakst, Vishal Gupta, Brett Miles, Eric Michael Genden, Marshall R. Posner, Krzysztof Misiukiewicz
Journal: Journal of Clinical Oncology (2014)

e17009 Background: There is a clinical need to improve outcomes for patients with locally advanced HPV negative SCCHN. Cabazitaxel prolongs survival in patients with docetaxel refractory prostate cancer. The primary objective of this study is to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of cabazitaxel when combined with cisplatin and 5-fluorouracil (PF) in Induction chemotherapy (IC) for patients with incident SCCHN. The secondary objective is to assess response rate, progression-free survival and overall survival. Methods: This phase I study employed a standard 3+3 design and DLT defined as grade 4 or 5 toxicity or grade 3 toxicity lasting > 7 days. Twenty-six eligible patients (24M, 2F) were enrolled: 13 oropharynx, 8 larynx, 1 oral tongue, 1 nasopharynx and 3 hypopharynx. HPV status was primarily determined by p16 IHC for oropharynx cases: 9 positive, 2 negative and 2 not evaluated. Five dose levels of tri-weekly cabazitaxel were tested in combination with cisplatin 100 mg/m2 and 5-FU 3200 mg/m2 over 4 days (Table 1). Dose escalation for cabazitaxel was terminated and 3 dose levels were then tested with cisplatin 75 mg/m2 and 5-fluorouracil (FU) 3200 mg/m2. Following 3 cycles of IC, patients were evaluated for clinical, radiographic, and pathologic response to cabazitaxel-PF before beginning chemoradiotherapy. Results: Main toxicities seen in cohorts 1-5 were thrombocytopenia, anemia, fatigue, nausea, diarrhea, constipation, and mucositis; in cohorts -1 to -3 were mucositis, nausea, and fatigue. There were two DLTs (grade 4 hyperuricemia; grade 4 neutropenic fever, sepsis, acute respiratory failure, and thrombocytopenia) among 2 patients in cohort 5. There were 17 responders, 8 non-responders, 1 lost to follow-up and no treatment-related deaths. Conclusions: The recommended phase II dose for cabazitaxel in combination with 5-FU 3200 mg/m2 and cisplatin 75 mg/m2 is 22.5 mg/m2. Clinical trial information: NCT01379339. Cohort Cabazitaxel (mg/m2) Cisplatin (mg/m2) 5-Fluorouracil (mg/m2) # of Patients 1 10 100 3200 3 2 12.5 100 3200 3 3 15 100 3200 3 4 17.5 100 3200 3 5 20 100 3200 5 -1 17.5 75 3200 3 -2 20 75 3200 3 -3 22.5 75 3200 3
INVASIVE MANAGEMENT STRATEGIES AND ANTI-THROMBOTIC TREATMENTS IN PATIENTS WITH NSTE-ACS IN CHINA
Authors: Qing Yang, Ying Wang, Jing Liu, Jun Liu, Yongchen Hao, Sidney C. Smith, Yong Huo, Gregg C. Fonarow, Changsheng Ma, Junbo Ge, Kathryn A. Taubert, Morgan Louise, Yang Guo, Wei Wang, Yujie Zhou, Dong Zhao
Journal: Journal of the American College of Cardiology (2017)
Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC)
Authors: C. Nabhan, K. Tolzien, T. M. Lestingi, A. Galvez, J. D. Bitran
Journal: Journal of Clinical Oncology (2009)

e16105 Background: There is no standard for CRPC once chemotherapy fails. In studies employing docetaxel (D), 35–39% of pts did not complete therapy due to progression and only 45–50% had a PSA response. This implies that many pts develop resistance to D. Sorafenib is a multi kinase inhibitor with antiangiogenesis properties. We hypothesized that sorafenib could overcome chemotherapy resistance in these pts. Methods: Eligible pts must have progressed while on either D or mitoxantrone (M). They received sorafenib at 400 mg orally twice/daily in addition to the chemotherapy agent they were on. Sorefinib/chemotherapy combination was given for a maximum of 6 cycles followed by sorafenib monotherapy until progression. Primary end point was safety of the sorafenib/chemotherapy combination. Secondary end points included the overall clinical benefit calculated as the sum of complete response (CR), partial response (PR), and stable disease (SD), toxicity, and time to disease progression (TTP). Results: To date, 15 pts have been enrolled; 14 are evaluable. Eleven pts were on D and 4 on M. Median age was 68 (range 61–83), median PSA was 111.2 ng/ml (13.6–1703.9). Nine pts (60%) had visceral and bone disease. Median PSA-DT pre-study was 2 months (0.5–6) and median time from last chemotherapy to starting study was 4 weeks. Median number of given cycles was 6.5 (2–12). Six pts did not require dose reduction, 2 others were re-escalated to the full dose. Sorafenib was safely combined with chemotherapy with 6 pts experiencing grade 3 fatigue, 3 developing grade 3 hand/foot syndrome, and 1 experiening grade 3 diarrhea. Eleven pts (73%) had SD radiographically that lasted a median of 6.7 months. In all, 6 out of 14 pts (42%) had a PSA decline after adding sorafenib and 3 (21%) had stable PSA. Of these 9 pts (PR+SD), 2 never doubled their PSA. Two pts had PSA decline after withdrawing sorafenib. Median TTP for PSA was 3.75 months. PSA responses did not correlate with radiographic changes or clinical benefit. With a median follow-up of 8 months, 5 pts (33%) remain alive with 1 continuing on therapy without progression. Conclusions: Sorafenib overcomes chemotherapy-refractoriness and failures in CRPC. [Table: see text]
Genetic Susceptibility Loci for Childhood Acute Lymphoblastic Leukemia Among Japanese
Authors: Kevin Y Urayama, Masatoshi Takagi, Takahisa Kawaguchi, Keitaro Matsuo, Yoichi Tanaka, Yuki Arakawa, Daisuke Hasegawa, Yuki Yuza, Takashi Kaneko, Yasushi Noguchi, Yuichi Taneyama, Setsuo Ota, Takeshi Inukai, Masakatsu Yanagimachi, Dai Keino, Kazutoshi Koike, Daisuke Toyama, Yozo Nakazawa, Hidemitsu Kurosawa, Kozue Nakamura, Koichi Moriwaki, Hiroaki Goto, Yujin Sekinaka, Daisuke Morita, Motohiro Kato, Katsuyoshi Koh, Yasushi Ishida, Akira Ohara, Shuki Mizutani, Fumihiko Matsuda, Atsushi Manabe
Journal: Blood (2015)
PREDICTORS OF NEW-ONSET ATRIAL FIBRILLATION IN ESSENTIAL HYPERTENSIVES
Authors: Dimitris Konstantinidis, Konstantinos Tsioufis, Kyriakos Dimitriadis, Dimitris Tsiachris, Alexandros Kasiakogias, Velissaris Antonakis, E. Andrikou, Dimitrios Aragianis, Dimitrios Tousoulis
Journal: Journal of the American College of Cardiology (2017)
SUSTAINED CLINICAL BENEFIT OF CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH RELATIVELY PRESERVED EJECTION FRACTION: A MADIT-CRT LONG-TERM FOLLOW-UP SUB-STUDY
Authors: Katherine Vermilye, Usama Daimee, Scott Solomon, Scott McNitt, Wojciech Zareba, Arthur Moss, Valentina Kutyifa
Journal: Journal of the American College of Cardiology (2017)
PROBNP STRONGLY PREDICTS FUTURE VASCULAR EVENTS IN ANGIOGRAPHIED CORONARY PATIENTS WITH AS WELL AS IN THOSE WITHOUT THE METABOLIC SYNDROME
Authors: Philipp Rein, Daniela Zanolin, Andreas Leiherer, Alexander Vonbank, Christoph H. Saely, Heinz Drexel
Journal: Journal of the American College of Cardiology (2017)
Inform Parents, Protect High School Blood Donors
Authors: Anne F. Eder, Harvey G. Klein, Cathy Conry-Cantilena
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
LIFELONG BURDEN OF VITAMIN D DEFICIENCY INCREASES CLINICAL CARDIAC EVENTS AND DEATH UNRAVELED BY AN EXOME CHIP-DERIVED MULTI-LOCI GENETIC RISK SCORE: A MENDELIAN-RANDOMIZED STUDY
Authors: Will Chan, Tai-Hing Lam, G. Neil Thomas, Chao-Qiang Jiang, Pak-Chung Sham, Mary Schooling, Benjamin Cowling, Kar-Keung Cheng, Karen Siu-Ling Lam, Hung-Fat Tse
Journal: Journal of the American College of Cardiology (2017)
Intra-arterial infusion of recombinant adenoviral human p53 gene combined chemotherapy for advanced oral cancer: A phase II double-blind randomized clinical trial.
Authors: Yi Li, Longjiang Li
Journal: Journal of Clinical Oncology (2012)

5507 Background: The p53 tumor suppressor gene has been shown as having multiple anti-tumor functions and being capable of enhancing the efficacy of chemo-therapy. This study is to investigates clinical outcomes of intra-arterial infusion ofrecombinant adenoviral human p53 gene (rAd-p53) combined with chemotherapy in treatment of advanced oral cancer. Methods: Ninety-nine patients with stage III or IV oral carcinoma, satisfying with the inclusion criteria, were randomly allocated to Group I (G1: n=35; rAd-p53 plus chemotherapy), Group II (G2: n=33; rAd-p53), or Group III (G3: n=31; chemotherapy). Intra-artery infusion of rAd-p53 were given through superficial temporal artery reverse intubation at a dose 1-4 ×10 12 viral particles (VP) , once every 3 days for 6 times. Chemotherapy regimen consisted of oxaplatin 200 mg/m 2 on day1, bleomycin 8 mg/m 2 on day 2, 6, 8 and Methotrexate 30 mg/m 2 on day1, 8, for squamous cell carcinoma (SCC), and oxaplatin 200 mg/m 2 on day1, 5-Fu 200 mg/m 2 on day1,3 and cyclophosphamide 400 mg/m 2 on day2, 8 for adenoid cystic carcinoma (ACC). Results: The complete response rate (CR) in G1 (48.5%) was significantly higher than in G2 (16.7%) and G3 (17.2%). The overall response rates (RR) were 88.6%, 54.5%, and 51.6% for G1, G2 and G3, respectively. The 3-year overall survival (OS) of G1 (82.9%) was significantly higher than the patients in G2 (60.6%) and G3 (58.1%). All those patients receiving rAd-p53 had a self-limited fever. Positive Bax immunostaining was detected in all the patients receiving rAd-p53. Conclusions: Intra-arterial infusion of combined rAd-p53 and chemotherapy may represent an alternative to the current standard treatment for the late stage oral carcinoma.
Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.
Authors: Tulika Ranjan, Katherine B. Peters, Gordana Vlahovic, Lloyd M Alderson, James Emmett Herndon, Frances McSherry, Stevie Threatt, John Howard Sampson, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman, James J Vredenburgh, Annick Desjardins
Journal: Journal of Clinical Oncology (2013)

e13015^ Background: Standard treatment for GBM includes RT and TMZ, followed by six cycles of TMZ, for a median overall survival (OS) and progression-free survival (PFS) of 14.6 and 6.9 months, respectively. BV is FDA approved for recurrent GBM and carmustine wafers are approved for newly diagnosed and recurrent GBM. We evaluated the safety and efficacy of carmustine wafers insertion followed by concurrent RT, TMZ and BV, followed by TMZ and BV for newly diagnosed GBM patients. Methods: Treatment consisted of: Part A- carmustine wafers insertion at resection followed by RT and TMZ at 75 mg/m 2 /day. BV at 10 mg/kg every two weeks started at least 28 days post-operatively. Part B- Patients received 12 cycles of TMZ (200 mg/m 2 on days 1-5 of a 28-day cycle) and BV every two weeks (day 1 and 15). Results: Forty one patients of a planned accrual of 72 were enrolled. The study was closed early due to six grade 4-5 toxicities related to study intervention, which met the safety criteria to discontinue the trial. Three patients had grade 4 cerebral edema and one each had grade 4 fatigue, wound infection and meningitis. Median age was 56 years (range, 27-77 years) and 28 patients were men. Of 41 patients, 36 completed part A and 31 started part B. Eleven patients are still on study and 4 have completed part B. Twenty six patients are off study due to progression (n = 16), adverse events (n = 8) and consent withdrawal (n = 2). At a median follow-up of 12.6 months (95% CI: 10.8-15.6 months) the median PFS is 11.3 months (95% CI: 9.2-12.9 months) and the median OS is 16.1 months (95% CI: 15.8 months- ∞). Grade 3-5 toxicities so far include: thrombocytopenia (grade 3, n = 2; grade 4, n = 2), stroke (grade 3, n = 1; grade 5, n = 1), infection (grade 3, n = 2), meningitis (grade 3, n = 1; grade 4, n=1), venous thromboembolic events (grade 3, n = 5), cerebral edema (grade 4, n = 3), fatigue (grade 4, n = 1), enterocolitis (grade 3, n = 1), and wound infection (grade 3, n = 2; grade 4, n = 1). Conclusions: For the patients who did well post carmustine wafers insertion, the treatment was tolerable and median PFS and OS has improved. Updated survival and toxicity results will be presented. Clinical trial information: NT01186406.
Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive (HR<sup>+</sup>), HER2-negative (HER2<sup>–</sup>) advanced breast cancer (ABC) in Europe.
Authors: Guy Heinrich Maria Jerusalem, Patrick Neven, Nina Marinsek, Jie Zhang, Ravi Degun, Giancarlo Benelli, Stephen Saletan, Fabrice Andre
Journal: Journal of Clinical Oncology (2013)

e17520 Background: Healthcare resource utilization varies by disease stage and treatment choice. Notably, chemotherapy (CT) use is associated with extensive healthcare resource utilization and cost. This study reviews the direct and indirect cost implications of CT versus hormonal therapy (HT) in the ABC setting through the first 3 lines of treatment. Methods: A retrospective chart review of postmenopausal women diagnosed with HR + , HER2 – ABC in 5 European countries was conducted. Patients must have progressed on at least 1 line of HT and completed at least 1 line of CT in the ABC setting. Patient cohorts based on therapy received in each line were constructed (cohort A: HT 1st-line, CT 2nd-line, and any treatment 3rd-line; cohort B: HT 1st- and 2nd-line with CT 3rd-line; and cohort C: CT 1st-line with any 2nd- and 3rd-line). Costs of care based on resource utilization and country-specific cost were calculated by patient cohort and line of therapy. Working status was also assessed. Results: A total of 355 eligible patient charts between 2008 and 2012 were included in the analysis: cohort A, 218 (61%) patients; cohort B, 26 (7%) patients; and cohort C 111 (31%) patients. Total direct costs over all 3 treatment lines were €14,362 higher for CT versus HT as 1st-line therapy (cohort C vs A) and €10,368 higher for CT versus HT as 2nd-line (cohort A vs B). Monthly direct costs were €2,536 higher for CT versus HT for 1st-line therapy and €1,713 higher for CT versus HT in 2nd-line. Increased costs for CT were due to treatments to manage side effects, use of concomitant targeted therapies, and increased frequency of hospitalizations, healthcare provider visits, and monitoring tests. On switching from HT to CT, there was a doubling of the proportion of patients on sick leaves in both cohorts A and B. Conclusions: These results suggest an increased direct cost of care for CT relative to HT in European postmenopausal women with HR + , HER2 – ABC. Furthermore, CT-based therapy appears to be associated with lower productivity of working-age patients, potentially increasing overall indirect costs.
PROGNOSTIC IMPACT OF GERIATRIC NUTRITIONAL RISK INDEX IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Hideki Wada, Tomotaka Dohi, Katsumi Miyauchi, Shuta Tsuboi, Manabu Ogita, Takatoshi Kasai, Satoru Suwa, Hiroyuki Daida
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF ACTIVE CORONARY ARTERY DISEASE ON THE EARLY AND 1 YEAR MORTALITY OF PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Kesavan Sankaramangalam, Kinjal Banerjee, Brandon Jones, Krishna Kandregula, Yash Jobanputra, Lars Svensson, Samir Kapadia
Journal: Journal of the American College of Cardiology (2017)
Topical ketamine-amitriptyline-lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability
Authors: Helen G. Lee, Shoshana K. Grossman, Rodrigo Valdes-Rodriguez, Francis Berenato, Jack Korbutov, Yiong-Huak Chan, Michael Joseph Lavery, Gil Yosipovitch
Journal: Journal of the American Academy of Dermatology (2017)
A phase II study of the tolerability and activity of weekly vincristine sulfate liposomes injection (VSLI) in adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second relapse or progressing following two antileukemia treatment lines
Authors: L. T. Heffner, L. E. Damon, M. L. Larson, G. Schiller, W. Stock, H. M. Kantarjian, B. Lu, S. M. Imperiale, S. O'Brien
Journal: Journal of Clinical Oncology (2009)

7046 Background: VSLI (Marqibo) is a nanoparticle formulation of vincristine sulfate (VCR) encapsulated in sphingomyelin/cholesterol liposomes called Optisomes. The optisomal formulation lends itself to an improved pharmacokinetic profile and enhanced tumor penetration and concentration. Preclinical studies of VSLI showed enhanced efficacy versus standard VCR in a variety of solid and hematologic malignancies. VSLI has a maximum tolerated dose of 2.25 mg/m 2 with no dose cap, while conventional VCR is dosed at 1.4 mg/m 2 with a 2 mg dose cap. A previous study in relapsed ALL showed a complete response rate of 19%, warranting further study. Methods: Eligible adult subjects received single agent intravenous VSLI at a dose of 2.25 mg/m 2 weekly with no dose cap. This international, multicenter, single-arm study will enroll approximately 56 subjects. Major endpoints include response rate and overall survival (OS). An interim analysis was planned following enrollment of 29 evaluable subjects. Results: 29 heavily pretreated subjects received ≥ 1 dose of VSLI. To date, at least 9 of 29 subjects had clearing of leukemic blasts and achievement of an M1 bone marrow. Based on preliminary data, the median OS is estimated to be 7.5 months (95% CI: 4.7–10.5) using the Kaplan-Meier method. The most frequent related adverse event (AE) was peripheral neuropathy (PN) (48%), half of which was grade 3. No grade 4 PN was reported. Six subjects had 8 treatment-associated grade 4 AEs of neutropenia (4), thrombocytopenia (2), anemia (1), and inappropriate antidiuretic hormone secretion (1). Conclusions: These results are encouraging, as VSLI was given as a single agent to a heavily pretreated patient population who nearly universally received prior VCR. This population typically has a very low response rate to anti-leukemia therapies. Early OS data compares favorably to an historical median OS of ∼ 2 months (8.7 weeks) in a second salvage population (data on file, M. D. Anderson). VSLI was well tolerated in these patients in the context of universal prior vincristine treatment. [Table: see text]
COMPARATIVE OUTCOMES OF ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND ANGIOTENSIN RECEPTOR BLOCKER IN DIABETIC HYPERTENSIVE ACUTE MYOCARDIAL INFARCTION PATIENTS: RESULTS FROM THE KOREA ACUTE MYOCARDIAL INFARCTION REGISTRY (KAMIR)
Authors: Seung-Woon Rha, Min Shim, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Jun Hyuk Kang, Woo Hyeun Kim, Sung Hun Park, Eun Jin Park, Jah Yeon Choi, Sunki Lee, Hu Li, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong-Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2017)
Anaplastic Thyroid Cancer: A report of 5 consecutive cases treated successfully with nab-Paclitaxel.
Authors: Andrew Peter Dean, Robin Yeong Hong Goh, Peter Smith
Journal: Journal of Clinical Oncology (2015)

e17095 Background: Advanced anaplastic thyroid cancer is a disease with very few treatment options. Poor response rates have been reported with cisplatin / doxorubicin and modest response noted in a single phase 2 trial with 24 hour paclitaxel infusion. The 50% response rate has not been reproduced by other investigators but raises questions about the possible utility of taxanes. Although paclitaxel is not approved for this indication in Australia, nab-Paclitaxel is available on a compassionate access scheme. We report 5 consecutive cases treated with nab-paclitaxel (as an alternative to paclitaxel infusion) who all exhibited a response to treatment. Methods: 5 consecutive patients with histologically proven advanced anaplastic thyroid cancer were assessed and imaged to document extent of disease. They were all treated with nab-paclitaxel 100mg/M2 given weekly either continuously or for 3 weeks out of every 4. Clinical and radiological response to treatment was documented. Results: The number of cycles given ranged from 3 to 8. Two patients required dose reductions due to neuropathy. Of the 5 patients 4 had measurable metastatic disease, 4 had measurable local disease and 3 were treated surgically. Four patients showed clinical response to treatment with shrinkage of measurable local disease. Two patients with stridor developed considerable relief from this distressing symptom. One patient had been fully resected (Stage 4B) prior to chemotherapy but with extensive lympho-vascular invasion present. Two patients, (1 Stage 4B and 1 Stage 4C) considered inoperable by a specialist thyroid surgeon, were able to undergo successful thyroid surgery after 4 and 6 cycles of treatment. The patient with no evaluable disease after resection (Stage 4B) who received adjuvant nab-paclitaxel remains free of recurrence at 3 years. Conclusions: Anaplastic thyroid cancer is generally regarded as malignancy untreatable by chemotherapy. Our pilot series suggests nab-Paclitaxel warrants further evaluation. Analysis of SPARC status is planned.